Astex targets CNS with fragment-based approach

Building on success in the oncology field, Astex Pharmaceuticals is applying its fragment based drug discovery (FBDD) platform to new neurodegenerative disease targets.

Oct 25, 2016
1
0
Page of

Astex Pharmaceuticals

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.

No comments yet.